相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis
Stephen A. Harrison et al.
GASTROENTEROLOGY (2021)
Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH
Rohit Loomba et al.
HEPATOLOGY (2021)
A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
Philip N. Newsome et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Ability of Noninvasive Scoring Systems to Identify Individuals in the Population at Risk for Severe Liver Disease
Hannes Hagstrom et al.
GASTROENTEROLOGY (2020)
A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe
Jeffrey Lazarus et al.
JOURNAL OF HEPATOLOGY (2020)
Economic and Clinical Burden of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes in the US
Zobair M. Younossi et al.
DIABETES CARE (2020)
Effect of Metabolic Traits on the Risk of Cirrhosis and Hepatocellular Cancer in Nonalcoholic Fatty Liver Disease
Fasiha Kanwal et al.
HEPATOLOGY (2020)
Patatin-Like Phospholipase Domain-Containing Protein 3 I148M and Liver Fat and Fibrosis Scores Predict Liver Disease Mortality in the US Population
Aynur Unalp-Arida et al.
HEPATOLOGY (2020)
Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology
Mohammed Eslam et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2020)
Modelling NAFLD disease burden in four Asian regions-2019-2030
Chris Estes et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)
Vitamin E Improves Transplant-Free Survival and Hepatic Decompensation Among Patients With Nonalcoholic Steatohepatitis and Advanced Fibrosis
Eduardo Vilar-Gomez et al.
HEPATOLOGY (2020)
Toward Genetic Prediction of Nonalcoholic Fatty Liver Disease Trajectories: PNPLA3 and Beyond
Marcin Krawczyk et al.
GASTROENTEROLOGY (2020)
Association Between Fibrosis Stage and Outcomes of Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis
Rod S. Taylor et al.
GASTROENTEROLOGY (2020)
Redefining non-alcoholic fatty liver disease: what's in a name?
[Anonymous]
LANCET GASTROENTEROLOGY & HEPATOLOGY (2020)
Nonalcoholic fatty liver disease: modulating gut microbiota to improve severity?
Judith Aron-Wisnewsky et al.
GASTROENTEROLOGY (2020)
Therapeutic landscape for NAFLD in 2020
Brent A. Neuschwander-Tetri
GASTROENTEROLOGY (2020)
Adipose Tissue-Liver Cross Talk in the Control of Whole-Body Metabolism: Implications in Nonalcoholic Fatty Liver Disease
Vian Azzu et al.
GASTROENTEROLOGY (2020)
Serial Transient Elastography Examinations to Monitor Patients With Type 2 Diabetes: A Prospective Cohort Study
Hye Won Lee et al.
HEPATOLOGY (2020)
Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLD
James M. Paik et al.
HEPATOLOGY (2020)
Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials
Stephen A. Harrison et al.
JOURNAL OF HEPATOLOGY (2020)
A diabetologist's perspective of non-alcoholic steatohepatitis (NASH): Knowledge gaps and future directions
Kenneth Cusi
LIVER INTERNATIONAL (2020)
Liver stiffness measurement predicts long-term survival and complications in non-alcoholic fatty liver disease
Sarah Shili-Masmoudi et al.
LIVER INTERNATIONAL (2020)
FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study
Philip N. Newsome et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2020)
Review article: the emerging role of genetics in precision medicine for patients with non-alcoholic steatohepatitis
Bjorn Carlsson et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)
Predictors of advanced fibrosis in elderly patients with biopsy-confirmed nonalcoholic fatty liver disease: the GOASIA study
Panyavee Pitisuttithum et al.
BMC GASTROENTEROLOGY (2020)
Protocol for a randomised trial testing a community fibrosis assessment service for patients with suspected non-alcoholic fatty liver disease: LOCal assessment and triage evaluation of non-alcoholic fatty liver disease (LOCATE-NAFLD)
David Brain et al.
BMC HEALTH SERVICES RESEARCH (2020)
SGLT2 Inhibitors in Liver Patients
John Chen Hsiang et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2020)
Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores
Giovanni Targher et al.
GUT (2020)
NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications
Giovanni Targher et al.
GUT (2020)
Confounding factors of non-invasive tests for nonalcoholic fatty liver disease
Janae Wentong Wai et al.
JOURNAL OF GASTROENTEROLOGY (2020)
STELLAR 3 and STELLAR 4: Lessons from the fall of Icarus
Mary E. Rinella et al.
JOURNAL OF HEPATOLOGY (2020)
A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement
Mohammed Eslam et al.
JOURNAL OF HEPATOLOGY (2020)
Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies
Helen Jarvis et al.
PLOS MEDICINE (2020)
Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis
Qing Ye et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2020)
Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5
Robert F. Kushner et al.
OBESITY (2020)
Bariatric Surgery Provides Long-term Resolution of Nonalcoholic Steatohepatitis and Regression of Fibrosis
Guillaume Lassailly et al.
GASTROENTEROLOGY (2020)
A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study
Stephen A. Harrison et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2020)
Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials
Beth A. Davison et al.
JOURNAL OF HEPATOLOGY (2020)
NAFLD - sounding the alarm on a silent epidemic
Jeffrey V. Lazarus et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2020)
Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association
Byung-Wan Lee et al.
DIABETES & METABOLISM JOURNAL (2020)
Development and implementation of a commissioned pathway for the identification and stratification of liver disease in the community
Jane Chalmers et al.
FRONTLINE GASTROENTEROLOGY (2020)
Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease
Mohammad S. Siddiqui et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2019)
ADAPT: An Algorithm Incorporating PRO-C3 Accurately Identifies Patients With NAFLD and Advanced Fibrosis
Samuel J. Daniels et al.
HEPATOLOGY (2019)
Burden of Illness and Economic Model for Patients With Nonalcoholic Steatohepatitis in the United States
Zobair M. Younossi et al.
HEPATOLOGY (2019)
Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
Peter J. Eddowes et al.
GASTROENTEROLOGY (2019)
A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver disease
Cyrielle Caussy et al.
NATURE COMMUNICATIONS (2019)
Outcomes of liver transplantation for non-alcoholic steatohepatitis: A European Liver Transplant Registry study
Debashis Haldar et al.
JOURNAL OF HEPATOLOGY (2019)
Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease
Ankur Srivastava et al.
JOURNAL OF HEPATOLOGY (2019)
Past, present and future perspectives in nonalcoholic fatty liver disease
Arun J. Sanyal
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2019)
Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial
Fernando Bril et al.
DIABETES CARE (2019)
Report on the AASLD/EASL Joint Workshop on Clinical Trial Endpoints in NAFLD
Mary E. Rinella et al.
HEPATOLOGY (2019)
Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials
Quentin M. Anstee et al.
HEPATOLOGY (2019)
The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis
Zobair M. Younossi et al.
JOURNAL OF HEPATOLOGY (2019)
The risk of incident extrahepatic cancers is higher in non-alcoholic fatty liver disease than obesity - A longitudinal cohort study
Alina M. Allen et al.
JOURNAL OF HEPATOLOGY (2019)
CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients
Paul J. Pockros et al.
LIVER INTERNATIONAL (2019)
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Stephen A. Harrison et al.
LANCET (2019)
Unified interpretation of liver stiffness measurement by M and XL probes in non-alcoholic fatty liver disease
Vincent Wai-Sun Wong et al.
GUT (2019)
Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics
Stergios A. Polyzos et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2019)
Adipose tissue-associated cancer risk: Is it the fat around the liver, or the fat inside the liver?
Giulio Marchesini et al.
JOURNAL OF HEPATOLOGY (2019)
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
Zobair M. Younossi et al.
LANCET (2019)
Impact of Implementing a FIB-4 First Strategy on a Pathway for Patients With NAFLD Referred From Primary Care
Tracy Davyduke et al.
HEPATOLOGY COMMUNICATIONS (2019)
Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease
David E. Kleiner et al.
JAMA NETWORK OPEN (2019)
Macrophages in obesity and non-alcoholic fatty liver disease: Crosstalk with metabolism
Sander Lefere et al.
JHEP REPORTS (2019)
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
Naga Chalasani et al.
HEPATOLOGY (2018)
Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease
Chris Estes et al.
HEPATOLOGY (2018)
Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017Part 1: Definition, risk factors and assessment
Vincent Wai-Sun Wong et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2018)
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Zobair Younossi et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2018)
Improved Diet Quality Associates With Reduction in Liver Fat, Particularly in Individuals With High Genetic Risk Scores for Nonalcoholic Fatty Liver Disease
Jiantao Ma et al.
GASTROENTEROLOGY (2018)
Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study
Eduardo Vilar-Gomez et al.
GASTROENTEROLOGY (2018)
Healthcare Cost and Utilization in Nonalcoholic Fatty Liver Disease: Real-World Data From a Large US Claims Database
Alina M. Allen et al.
HEPATOLOGY (2018)
Noninvasive, Quantitative Assessment of Liver Fat by MRI-PDFF as an Endpoint in NASH Trials
Cyrielle Caussy et al.
HEPATOLOGY (2018)
Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: A 20 year-community study
Alina M. Allen et al.
HEPATOLOGY (2018)
Trends in Obesity and Severe Obesity Prevalence in US Youth and Adults by Sex and Age, 2007-2008 to 2015-2016
Craig M. Hales et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Physical activity levels and hepatic steatosis: A longitudinal follow-up study in adults
Aline Mendes Gerage et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2018)
The PNPLA3 SNP rs738409:G allele is associated with increased liver disease-associated mortality but reduced overall mortality in a population-based cohort
Peter J. Meffert et al.
JOURNAL OF HEPATOLOGY (2018)
Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030
Chris Estes et al.
JOURNAL OF HEPATOLOGY (2018)
Non-invasive prediction of esophageal varices by stiffness and platelet in non-alcoholic fatty liver disease cirrhosis
Salvatore Petta et al.
JOURNAL OF HEPATOLOGY (2018)
Mechanisms of NAFLD development and therapeutic strategies
Scott L. Friedman et al.
NATURE MEDICINE (2018)
Noninvasive biomarkers in NAFLD and NASH - current progress and future promise
Vincent Wai-Sun Wong et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2018)
Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease
Myriam Alexander et al.
BMC MEDICINE (2018)
The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options
Zobair Younossi et al.
JOURNAL OF HEPATOLOGY (2018)
Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial
Patrick M. O'Neil et al.
LANCET (2018)
Hepatocyte-secreted DPP4 in obesity promotes adipose inflammation and insulin resistance
Devram S. Ghorpade et al.
NATURE (2018)
Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease
Fasiha Kanwal et al.
GASTROENTEROLOGY (2018)
Local care and treatment of liver disease (LOCATE) - A cluster-randomized feasibility study to discover, assess and manage early liver disease in primary care
Magdy El-Gohary et al.
PLOS ONE (2018)
Non-alcoholic fatty liver disease and the interface between primary and secondary care
Emmanuel A. Tsochatzis et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2018)
The preventive effect of sustained physical activity on incident nonalcoholic fatty liver disease
Min-Sun Kwak et al.
LIVER INTERNATIONAL (2017)
Magnetic Resonance Elastography vs Transient Elastography in Detection of Fibrosis and Noninvasive Measurement of Steatosis in Patients With Biopsy-Proven Nonalcoholic Fatty Liver Disease
Charlie C. Park et al.
GASTROENTEROLOGY (2017)
Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults
Majid Ezzati et al.
LANCET (2017)
Multimorbidity and polypharmacy in diabetic patients with NAFLD: Implications for disease severity and management
Preya Janubhai Patel et al.
MEDICINE (2017)
Adiposity amplifies the genetic risk of fatty liver disease conferred by multiple loci
Stefan Stender et al.
NATURE GENETICS (2017)
Prognostic Value of Controlled Attenuation Parameter by Transient Elastography
Ken Liu et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2017)
Diagnostic Accuracy of Noninvasive Fibrosis Scores in a Population of Individuals With a Low Prevalence of Fibrosis
Suzanne E. Mahady et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2017)
Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease
Rohit Loomba et al.
CELL METABOLISM (2017)
Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus A Randomized Trial
Kenneth Cusi et al.
ANNALS OF INTERNAL MEDICINE (2016)
Global Epidemiology of Nonalcoholic Fatty Liver Disease-Meta-Analytic Assessment of Prevalence, Incidence, and Outcomes
Zobair M. Younossi et al.
HEPATOLOGY (2016)
Effect of exercise on the development of new fatty liver and the resolution of existing fatty liver
Ki-Chul Sung et al.
JOURNAL OF HEPATOLOGY (2016)
EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
Giulio Marchesini et al.
JOURNAL OF HEPATOLOGY (2016)
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
Matthew James Armstrong et al.
LANCET (2016)
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Prevalence and Severity of Nonalcoholic Fatty Liver Disease in Non-Obese Patients: A Population Study Using Proton-Magnetic Resonance Spectroscopy
Jeremy Lok Wei et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2015)
Severity of Nonalcoholic Fatty Liver Disease and Progression to Cirrhosis Are Associated With Atherogenic Lipoprotein Profile
Mohammad S. Siddiqui et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2015)
Fibrosis Progression in Nonalcoholic Fatty Liver vs Nonalcoholic Steatohepatitis: A Systematic Review and Meta-analysis of Paired-Biopsy Studies
Siddharth Singh et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2015)
Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis
Eduardo Vilar-Gomez et al.
GASTROENTEROLOGY (2015)
Nonalcoholic Steatohepatitis Is the Second Leading Etiology of Liver Disease Among Adults Awaiting Liver Transplantation in the United States
Robert J. Wong et al.
GASTROENTEROLOGY (2015)
Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease
Paul Angulo et al.
GASTROENTEROLOGY (2015)
Fibrosis Stage Is the Strongest Predictor for Disease-Specific Mortality in NAFLD After Up to 33 Years of Follow-Up
Mattias Ekstedt et al.
HEPATOLOGY (2015)
Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: Implications for prognosis and clinical management
Stuart McPherson et al.
JOURNAL OF HEPATOLOGY (2015)
Expanding consensus in portal hypertension Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension
Roberto de Franchis
JOURNAL OF HEPATOLOGY (2015)
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
Brent A. Neuschwander-Tetri et al.
LANCET (2015)
Clinical value of liver ultrasound for the diagnosis of nonalcoholic fatty liver disease in overweight and obese patients
Fernando Bril et al.
LIVER INTERNATIONAL (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The Prevalence of Non-Alcoholic Fatty Liver Disease in Children and Adolescents: A Systematic Review and Meta-Analysis
Emma L. Anderson et al.
PLOS ONE (2015)
Utility and Appropriateness of the Fatty Liver Inhibition of Progression (FLIP) Algorithm and Steatosis, Activity, and Fibrosis (SAF) Score in the Evaluation of Biopsies of Nonalcoholic Fatty Liver Disease
Pierre Bedossa
HEPATOLOGY (2014)
Nonalcoholic Steatohepatitis Is the Most Rapidly Growing Indication for Liver Transplantation in Patients With Hepatocellular Carcinoma in the U. S.
Robert J. Wong et al.
HEPATOLOGY (2014)
A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver
Raluca Pais et al.
JOURNAL OF HEPATOLOGY (2013)
Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis
Quentin M. Anstee et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2013)
Pioglitazone for Diabetes Prevention in Impaired Glucose Tolerance
Ralph A. DeFronzo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study
Mariana Lazo et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis.
Arun J. Sanyal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Metabolic and histological features of non-alcoholic fatty liver disease patients with different serum alanine aminotransferase levels
V. W-S. Wong et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2009)
Performance of ELF Serum Markers in Predicting Fibrosis Stage in Pediatric Non-Alcoholic Fatty Liver Disease
Valerio Nobili et al.
GASTROENTEROLOGY (2009)
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Stefano Romeo et al.
NATURE GENETICS (2008)
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Renata Belfort et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C
AJ Sanyal et al.
HEPATOLOGY (2006)
Steatosis: Co-factor in other liver diseases
EE Powell et al.
HEPATOLOGY (2005)
The natural history of nonalcoholic fatty liver disease: A population-based cohort study
LA Adams et al.
GASTROENTEROLOGY (2005)
Sampling variability of liver biopsy in nonalcoholic fatty liver disease
V Ratziu et al.
GASTROENTEROLOGY (2005)
Nonalcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities
AJ Sanyal et al.
GASTROENTEROLOGY (2001)
分享论文
